Current market catalysts

U.S. Cyber, Law Enforcement Officials Accuse Chinese AI Companies Of 'Aggressive, Industrial-Scale Distillation Activities'

United Natural Foods Plans for More Inflation in 2027, Says Productivity, Not Price Hikes, Will Drive Margins

United Natural Foods (UNFI) beats Q4 EPS estimates and issues strong FY2027 guidance. Read the full earnings and stock performance report.

Tenable Integrates Anthropic’s Claude Mythos 5 Into Tenable One For AI-Powered Exposure Management

9 Communication Services Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

10 Industrials Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

10 Information Technology Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will

What's Going On With NVIDIA Stock Tuesday?

NVIDIA (NVDA) stock fell ~2% on Tuesday to $225.90, lagging tech sector gains despite broad market strength. Read the market analysis.

Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target

8-K filing — Federal Home Loan Bank of Cincinnati

Filed: 2026-09-08 AccNo: 0001326771-26-000147 Size: 157 KB Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Tesla Cybercab vs. Uber: Who Wins the Robotaxi Race?

Tesla and Uber are taking very different approaches to robotaxis. Here's which strategy could win the autonomous ride-hailing race.

HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $5

Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack

Boston Scientific expects a 2026 earnings miss after a cyberattack disrupted global operations. Manufacturing and shipping are recovering.

QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000

Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.

XRP, Bitcoin Have Moved in 'Near-Perfect Lockstep'—Here's What Could Change Soon

XRP may decouple from Bitcoin as an XRPL upgrade nears, but CPI and macro forces will test whether it can outperform independently.

HC Wainwright & Co. Maintains Buy on Sernova Biotherapeutics, Lowers Price Target to C$1

Goldman Stock Gains 38.6% in a Year: Buy Now or Wait for a Pullback?

Goldman Sachs (GS) has outperformed its industry peers with a 38.6% gain over the past year, driven by a 52% rise in investment banking fees, strong M&A activity, and ambitious AI transformation initiatives. The company's strategic streamlining, robust liquidity, and expansion in asset management support continued growth and shareholder returns. Analysts maintain a bullish outlook with upward earnings revisions, though the stock trades at a modest premium to industry peers.

Coca-Cola's Premiumization Push: Smart Strategy or Risky Move?

Coca-Cola is pursuing a balanced premiumization strategy across markets while maintaining affordability options for value-conscious consumers. The company uses brand strength, packaging variety, and occasion-based pricing to reach different income levels. However, risks remain as lower-income consumers face economic pressure globally. Peers PepsiCo and Monster Beverage are also pursuing similar premium strategies with measured approaches.

KTCC Stock Falls 35% as Q4 Loss Widens Y/Y Despite Revenue Rebound

Key Tronic Corporation (KTCC) shares fell 35.4% following Q4 fiscal 2026 results, which showed a GAAP net loss of $34.3 million despite improved gross margins. The company faced headwinds from supply chain credit constraints that delayed ~$10 million in shipments, along with a $28.4 million tax valuation allowance and $8.4 million in write-offs. However, management expects revenue growth and profitability recovery in fiscal 2027, supported by new program awards exceeding $60 million and restructuring initiatives including China exit and Vietnam expansion.

Chewy's Q2 Earnings on Deck: Will Strong Trends Continue?

Chewy is expected to report Q2 revenues of $3.32B (+6.8% YoY) and EPS of 36 cents (+9.1% YoY) on September 9. While the company benefits from strong Autoship adoption, customer reactivation, and healthcare expansion, cautious consumer spending, tougher margin comparisons, and elevated fuel surcharges pose near-term challenges. The Zacks model does not predict an earnings beat, with the stock carrying a Zacks Rank #4 (Sell) and negative Earnings ESP of -0.61%.

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

In a comparison of two medical-drugs stocks, Grifols (GRFS) emerges as the superior value option over Sandoz Group AG Sponsored ADR (SDZNY). GRFS has a stronger Zacks Rank of #2 (Buy) versus SDZNY's #3 (Hold), along with significantly better valuation metrics including a forward P/E of 7.03 compared to SDZNY's 20.54, a PEG ratio of 0.28 versus 1.77, and a P/B ratio of 0.57 versus 3.95. GRFS earned a Value grade of A while SDZNY received a C.

Argan's Q2 Beat Shows Power Strength as Industrial Margins Stay Soft

Argan, Inc. (AGX) reported strong Q2 fiscal 2027 results with earnings up 50.4% and revenue up 61.5%, beating consensus estimates. The Power segment drove margin strength with a 52.9% revenue increase and improved gross margins to 22.4%. However, Industrial revenues doubled but margins fell to 7.3% due to worsening project completion estimates. Management expects Industrial margins to remain below historical norms for another 1-2 quarters.

SSRM Advances With Marigold Growth Initiatives: Can They Aid Upside?

SSR Mining Inc. (SSRM) is advancing growth initiatives at its Marigold mine in Nevada, including the Buffalo Valley project, with an updated life-of-mine plan expected by end of 2026. The company expects 2026 Marigold production of 170,000-200,000 ounces, heavily weighted to Q4 with higher grades driving output. SSRM increased 2026 growth capital guidance from $48M to $65M and continues exploration at brownfield targets. The stock trades at a forward P/E of 9.55x, below industry average, with 2026 earnings consensus of $3.87/share (+92.5% YoY), though recent estimates have declined.

Is Argan Worth Buying as Growth Surges but Valuation Stays Elevated?

Argan Inc. reported 56.5% revenue growth and $126.5 million adjusted EBITDA in fiscal 2027's first half, supported by a $2.5 billion backlog. However, the company faces margin pressure with gross margins declining from 25% to 19.3%, and trades at a premium 31.1X forward earnings. While growth signals remain favorable, execution risks and uncertain project timing present challenges to justify the current valuation.

How Carlyle's Wealth Push Opens New Avenues for Fee Revenue Growth

The Carlyle Group is expanding its wealth-management business through strategic acquisitions and partnerships to increase private-market access for advisors and high-net-worth clients. The company acquired MAI Capital Management and Intelliflo, and partnered with SEI and UBS to strengthen its wealth platform. Carlyle targets $2.8 billion in management fees by 2028, up from $2.2 billion in 2025, with wealth and retirement expected to account for 20% of over $200 billion in targeted inflows.

PAX vs. KKR: Which Stock Is the Better Value Option?

A comparison of two Financial - Investment Management stocks reveals that Patria Investments (PAX) presents a better value opportunity than KKR & Co. Inc. (KKR). PAX holds a Zacks Rank #2 (Buy) with a forward P/E of 8.10 and Value grade of A, while KKR has a Zacks Rank #3 (Hold) with a forward P/E of 16.49 and Value grade of D. PAX demonstrates stronger earnings estimate revisions and more attractive valuation metrics across multiple indicators.

WaFd's EverBank Merger Deal: A Boost to Earnings & Scale?

WaFd, Inc. announced a planned merger with EverBank Financial Corp, expected to close in early 2027. The deal is projected to deliver 29% EPS accretion in 2027, improve funding stability through combined deposit bases, and expand commercial banking and wealth management capabilities. The combined company will be renamed EverBank Financial Corp with legacy EverBank investors owning 59.2% and WaFd shareholders holding 40.8%.

HAYW or MAIR: Which Is the Better Value Stock Right Now?

In a comparison of two Electronics - Miscellaneous Products stocks, Hayward Holdings (HAYW) and Madison Air Solutions (MAIR), both holding a Zacks Rank #2 (Buy), HAYW emerges as the superior value option. HAYW has a lower forward P/E ratio of 16.00 compared to MAIR's 23.40, a better P/B ratio of 1.84 versus 3.56, and earns a Value grade of B compared to MAIR's C grade.

SSUMY vs. CSL: Which Stock Is the Better Value Option?

In a comparison of two Diversified Operations sector stocks, Sumitomo Corp. (SSUMY) emerges as the superior value opportunity compared to Carlisle (CSL). SSUMY holds a Zacks Rank #1 (Strong Buy) with a forward P/E of 7.95 and Value grade of A, while CSL has a Zacks Rank #3 (Hold) with a forward P/E of 16.55 and Value grade of C. SSUMY's stronger earnings outlook and more attractive valuation metrics make it the better choice for value investors.

Here's Why You Should Retain AMN Stock in Your Portfolio for Now

AMN Healthcare Services expects Q3 nurse and allied staffing revenues to grow 9-11% driven by strong healthcare demand and expanding Managed Services Programs (MSPs) which now represent 46% of consolidated revenues. The company is diversifying through AI-enabled platforms and recent acquisitions. However, competitive pressures, declining language services revenues, and regulatory challenges pose risks to growth.

WF or CM: Which Is the Better Value Stock Right Now?

A comparison of two foreign banks shows Woori Bank (WF) presents a better value opportunity than Canadian Imperial Bank (CM). Woori Bank has a Zacks Rank of #2 (Buy) with a forward P/E of 8.32 and Value grade of B, while Canadian Imperial Bank has a Zacks Rank of #3 (Hold) with a forward P/E of 15.85 and Value grade of D. Woori Bank's lower valuation metrics and positive earnings revision trends make it the more attractive option for value investors.